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Radiotherapy is a mainstay of brain cancer treatment, but it causes significant complications. In this issue of
Cell Stem Cell, Piao et al. (2015) derive oligodendrocyte precursors from human embryonic stem cells and
show that engrafted cells replenish depleted precursor numbers, generate new myelin, and reverse behav-
ioral defects in irradiated rats.The therapeutic potential of oligodendro-
cyte precursor cell (OPC) transplantation
was first suggested by the pioneering
work of Gumpel and colleagues, who
showed widespread migration and myeli-
nation by transplanted cells in a mouse
mutant (shiverer) that lacks normal myelin
(Gansmuller et al., 1986). The more recent
demonstration by Goldman and col-
leagues that widespread and essentially
complete CNS myelination by OPCs
derived from human primary or pluripo-
tent cells can prolong survival in these
mice (Wang et al., 2013) confirms this po-
tential, establishing that transplantation
could in principle be used for diseases in
which myelin is lost or damaged.
A number of diseases can be consid-
ered targets for OPC transplantation
(Goldman et al., 2012). The hypomyelinat-
ing leukodystrophies, genetic disorders
in which myelin is not formed properly,
are the obvious first choice, given that
the microenvironment of the developing
CNS is most likely to be propitious for
myelination. A first-in-human study has
been performed in four children with an
early-onset form of one of these leuko-
dystrophies, Pelizaeus-Merzbacher dis-
ease, using a progenitor cell population
able to generate OPCs (Gupta et al.,
2012). No adverse effects have been
reported, and continued follow-up will
reveal whether this experimental medi-
cine approach leads to new myelin for-
mation. These diseases are however
very rare. The multifocal neuroinflamma-
tory disease multiple sclerosis (MS) is
more common, and transplantation might
be considered for particularly symptom-
atic lesions. However, the neuropa-
thology showing failed myelin regenera-tion even in the presence of abundant
endogenous OPCs suggests that, even
in those lesions that lack OPCs, environ-
mental factors might prevent transplanted
cells from forming myelin. For differing
reasons, therefore, neither leukodystro-
phies nor MS is an optimal target to drive
the translational and clinical investment
required for OPC transplantation to enter
mainstream clinical practice.
In this issue ofCell Stem Cell, Piao et al.
(2015) in the Tabar lab explore the feasi-
bility of OPC transplantation in another
disease situation that may be a more
attractive translational target: the seq-
uelae of cranial radiotherapy, a common
treatment for brain tumors (Figure 1).
This irradiation can cause profound
long-term damage, especially in children,
affecting cognition, information process-
ing, memory, and learning (Padovani
et al., 2012). The biological causes are
not fully understood, but candidate mech-
anisms include reduced neurogenesis as
well as reduction of the pool of oligoden-
drocyte progenitors and white matter
damage (Panagiotakos et al., 2007).
Although this is a major challenge in the
treatment of brain cancers, no effective
treatments have yet emerged for this
complication of cranial irradiation. The
paper by Piao and colleagues provides
proof-of-principle for an exciting new
approach based on OPC transplanta-
tion that could significantly improve the
lives of cancer patients after irradiation
therapy.
Piao et al. initially established that
whole-brain irradiation of immuno-
compromised nude rats resulted in OPC
depletion (as previously described by
Chari et al., 2006), white matter damage,Cell Stem Cell 16and concomitant behavioral defects
associated with learning, memory, and
motor skills, similar to results in human
patients. Transplantation of human em-
bryonic stem cell (hESC)-derived OPCs
into the corpus callosum of these rats
at 4 weeks post-irradiation lead to the
formation of human cell-derived myelin
sheaths and increased overall levels of
myelination in the damaged brains,
consistent with the observation of
Franklin et al. (1996) that OPCs can sur-
vive and migrate in the X-irradiated
CNS. Importantly, injection of the cells
was also associated with improvement
in the behavioral tests that measure
learning and memory, although there
was no improvement in motor skills and
coordination. In contrast to the earlier
work transplanting human induced
pluripotent stem cell (iPSC)-derived
OPCs into a myelination-deficient mouse
model (Wang et al., 2013), the OPCs did
not produce significant numbers of as-
trocytes and so the behavioral effects
cannot be attributed to them. To ask
why motor skills were not improved,
Piao et al. then performed a second set
of experiments in which they injected
hESC-derived OPCs into the cerebellum,
which is responsible for the control of
movement. Injection of OPCs into the
cerebellum resulted in remyelination of
this region, and motor improvement
was observed.
Translation of this approach into a ther-
apy for human disease will require that
additional questions be answered about
the transplantation protocol and the
source of transplanted cells. First, how
far will transplanted cells migrate? The
data showing that motor rescue requires, February 5, 2015 ª2015 Elsevier Inc. 113
Figure 1. Myelin Damage and the Potential for Repair by
Transplanted Human Stem Cell Derived-OPCs
Top: in the healthy brain oligodendrocytes myelinate axons (blue). Myelin
damage and loss (in green) occurs after radiotherapy or in inflammatory dis-
eases such as multiple sclerosis; whereas in leukodystrophies abnormal or
reduced myelination occurs during development. Bottom: radiotherapy
causes myelin damage in the brain associated with OPC depletion. Trans-
planted hESC-derived OPCs (orange) can generate new myelin resulting in
functional recovery in rats. (See text for more details.)
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migration distance to be
limited, and quantification of
cell migration will be required
for establishing optimal
transplantation protocols.
Second, what is the optimal
time window for transplanta-
tion after irradiation? Radia-
tion-induced white matter
tract damage develops over
years (Panagiotakos et al.,
2007) and, while ideally cells
would be transplanted shortly
after irradiation, the OPC
depletion that is thought to
be necessary for survival of
transplanted cells may not
yet have occurred. Third,
does age affect outcome?
Young children are most sus-
ceptible to radiation-induced
brain damage (Padovani
et al., 2012). Modeling this,
Piao et al. used very young
(4-week-old) rats, in which
myelination is still ongoing.
Will cells transplanted into
the older, adult brain stillmigrate, differentiate, and form myelin?
Even if they do, will the effects of irradia-
tion and of recovery posttransplantation
they observed also be seen in older,
adult rats—or in other words, might the
many adult patients irradiated for
CNS tumors see any benefit from OPC
transplants?
Regarding the optimal source of the
hOPCs for transplantation, hESC-derived
OPCs (or, if ongoing work in Japan and
elsewhere shows them to be safe for clin-
ical use, banked iPSCs) might be most
convenient. Mouse epiblast stem cell-
derived OPCs can be frozen, thawed,
and expanded by passaging to produce
large numbers of cells (Najm et al., 2011)
and, if this technique works with human
cells, large numbers of cells could be
created ‘‘off the shelf’’ for transplanta-
tion. However, patients would then need
immuno-suppressants to reduce the risk114 Cell Stem Cell 16, February 5, 2015 ª201of transplant rejection. Patient-specific
iPSCs would overcome this, but this
approach would not be realistic if the
time window established above is soon
after the irradiation, as making iPSCs
from individual patient samples would
add weeks to what is currently a long
and complex differentiation protocol of
70 days to make OPCs.
Alongside these questions, a broader
safety issue that needs to be addressed
is the risk of adverse effects of trans-
planted cells on the recipient (irradiated)
brain. Present experience would sug-
gest that the risk of transplanted OPCs
forming tumors is low, and Piao et al. did
not detect any tumors at 14 weeks post-
OPC injection. However, transplanted
cells will likely have a paracrine effect on
endogenous cells, as seen in many CNS
disease models. It will be essential to
consider whether endogenous tumor cells5 Elsevier Inc.can be reactivated by the
transplanted cells, thus
creating a risk of enhancing
the growth of the very tumor
the irradiation was designed
to prevent. It is to be hoped
that an increased interest
in the behavior of trans-
planted oligodendrocyte pre-
cursor cells in the irradiated
brain will answer these ques-
tions and lead to the clinical
trials necessary to ask defini-
tively whether the approach
will be effective for this debili-
tating complication of cranial
irradiation.
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